KR950704359A - 선충류 튜불린으로부터 유도된 펩티드 및 백신 - Google Patents
선충류 튜불린으로부터 유도된 펩티드 및 백신Info
- Publication number
- KR950704359A KR950704359A KR1019950701712A KR19950701712A KR950704359A KR 950704359 A KR950704359 A KR 950704359A KR 1019950701712 A KR1019950701712 A KR 1019950701712A KR 19950701712 A KR19950701712 A KR 19950701712A KR 950704359 A KR950704359 A KR 950704359A
- Authority
- KR
- South Korea
- Prior art keywords
- amino acid
- acid sequence
- sequence seq
- antibody
- vaccine
- Prior art date
Links
- 108090000704 Tubulin Proteins 0.000 title claims abstract description 11
- 229960005486 vaccine Drugs 0.000 title claims abstract 7
- 241000244206 Nematoda Species 0.000 title claims abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 3
- 102000004243 Tubulin Human genes 0.000 title description 9
- 208000036815 beta tubulin Diseases 0.000 claims abstract description 6
- 208000030852 Parasitic disease Diseases 0.000 claims abstract 5
- 239000012634 fragment Substances 0.000 claims abstract 5
- 102000000131 Beta tubulin Human genes 0.000 claims abstract 2
- 239000003096 antiparasitic agent Substances 0.000 claims abstract 2
- 229940125687 antiparasitic agent Drugs 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 210000004408 hybridoma Anatomy 0.000 claims abstract 2
- 244000045947 parasite Species 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 241000002163 Mesapamea fractilinea Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
본 발명은 선충류 유래 β-튜불린에 실직적으로 결합하는 모노클론 항체 및 그의 단편에 관한 것이다. 본 발명은 ATCC 기탁 번호 HB 11129로 기탁된 단일 클론항체를 생산하는 하이브리도마 세포주를 제공한다. 본 발명의 항체는 기생충 질환용 진단용 약 및 항기생충제로서 사용할 수 있다. 본 발명은 또한 백신 조성물 및 면역 제제로서 모노클론 항체에 의해 인식되는 항원의 용도에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 제1A도에서는 항-비, 피한지 β-튜불린 모노클론 항체를 사용하고 제1B도에서는 항-닭 뇌 튜불린 모노클론 항체를 사용하여 기생충, 돼지 뇌 및 3T3섬유아세포로부터의 추출물을 웨스턴 볼롯 분석한 도면.
제2도는 제2A도에서는 항-비, 피한지 β-튜불린 모노클론 항체 P3D를 사용하거나 제2B도에서는 항-비, 피한지 β-튜불린 모노클론 항체 1B6를 사용하여 성충 비, 피한지의 총 단백 추출물의 웨스턴 블롯 분석한 도면.
제3도는 제3A도에서는 항-비, 피한지 β-튜불린 모노클론 항체 P3D 및 제3B도에서는 항-비, 피한지 β-튜불린 모노클론 항체 1B6를 제한 단백분해한 생성물을 웨스턴 블롯 분석한 도면.
제4도는 항-비, 피한지 튜불린 모노클론 항체 P3D의 성숙 자성 비, 피한지의 생존력에 대한 시험관 내에서의 효과를 나타낸 그래프.
제5도는 항-비, 피한지 튜불린 모노클론 항체 1B6의 성숙 자성 비, 파한지의 생존력에 대한 시험관 내에서의 효과를 나타낸 그래프.
제6도는 항-닭 뇌 튜불린 모노클론 항체 357의 성숙 자성 비, 파한지의 생존력에 대한 시험관 내에서의 효과를 나타낸 그래프.
Claims (17)
- 선충류 유래의 β-튜불린에 실질적으로 결합한 모노클론 항체 및 그의 단편.
- 제1항의 모노클론 항체를 생산하며 ATCC에 기탁 번호 HB ll129로 기탁된 하이브리도마 세포주.
- 항기생충제로서의 제1항의 항체의 용도.
- 기생충 질환 진단용 약으로서의 제1항의 항체의 용도.
- 제3항에 있어서, 사상충증-유발 기생충에 대한 항체의 용도.
- 제4항에 있어서, 기생충 질환이 사상충증임을 특징으로 하는 용도.
- 하기의 아미노산 서열 SEQ ID NO : 1을 갖는 펩티드 또는 그의 단편의 기생충에 대한 면역제제로서의 용도.
- 적어도 하기의 아미노산 서열 SEQ ID NO : 1을 갖는 펩티드의 기생충에 대한 면역제제로서의 용도.
- 하기의 아미노산 서열 SEQ ID NO : 1을 갖는 펩티드 또는 그의 단편의 기생충에 대한 숙주에 의한 세포독성 항체의 생산을 유도하는 용도.
- 적어도 하기의 아미노산 서열 SEQ ID NO : 1을 갖는 펩티드의 기생충에 대한 숙주에 의한 세포독성 항체의 생산을 유도하는 용도.
- 하기의 아미노산 서열 SEQ ID NO : 1을 갖는 펩티드 또는 그의 단편 및 약제학적 담체로 이루어짐을 특징으로 하는 기생충 감염에 대한 백신.
- 적어도 하기의 아미노산 서열 SEQ ID NO : 1을 갖는 펩티드로 이루어짐을 특징으로 하는 기생충 감염에 대한 백신.
- 제11또는 12항에 따르는 백신을 투여함을 특징으로 하는 기생충에 대하여 포유류를 면역화시키는 방법.
- 제13항에 있어서, 기생충이 선충임을 특징으로 하는 방법.
- 제14항에 있어서, 선충이 심장사상충이고 포유류가 개임을 특징으로 하는 방법.
- 제13, 14 또는 15항에 있어서, 백신을 kg 체중 당 0.015㎍ 내지 0.15mg을 투여함을 특징으로 하는 방법.
- 제16항에 있어서, 백신을 kg 체중 당 1.5㎍ 내지 0.15mg을 투여함을 특징으로 하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96782992A | 1992-10-28 | 1992-10-28 | |
| US07/967,829 | 1992-10-28 | ||
| PCT/CA1993/000431 WO1994010201A1 (en) | 1992-10-28 | 1993-10-22 | Peptides and vaccines derived from nematode tubulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR950704359A true KR950704359A (ko) | 1995-11-20 |
Family
ID=25513395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950701712A KR950704359A (ko) | 1992-10-28 | 1993-11-22 | 선충류 튜불린으로부터 유도된 펩티드 및 백신 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0674659A1 (ko) |
| JP (1) | JPH08503935A (ko) |
| KR (1) | KR950704359A (ko) |
| AU (1) | AU5282193A (ko) |
| CA (1) | CA2147756A1 (ko) |
| WO (1) | WO1994010201A1 (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2404270A (en) | 2003-07-24 | 2005-01-26 | Hewlett Packard Development Co | Document composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0093775A1 (en) * | 1981-11-17 | 1983-11-16 | Brigham And Women's Hospital | Monoclonal antibodies against brugia malayi |
| GB2152510B (en) * | 1984-01-10 | 1988-06-15 | Kenneth K Lew | Method for the commercial production of helminths antigens |
| NL9001832A (nl) * | 1990-08-16 | 1992-03-16 | Rijksuniversiteit | Specifieke sequenties van dna van een nematode die toegepast kunnen worden bij de diagnostiek van infektie met de nematode. |
-
1993
- 1993-10-22 AU AU52821/93A patent/AU5282193A/en not_active Abandoned
- 1993-10-22 WO PCT/CA1993/000431 patent/WO1994010201A1/en not_active Application Discontinuation
- 1993-10-22 JP JP6510491A patent/JPH08503935A/ja active Pending
- 1993-10-22 CA CA002147756A patent/CA2147756A1/en not_active Abandoned
- 1993-10-22 EP EP93922866A patent/EP0674659A1/en not_active Withdrawn
- 1993-11-22 KR KR1019950701712A patent/KR950704359A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0674659A1 (en) | 1995-10-04 |
| JPH08503935A (ja) | 1996-04-30 |
| CA2147756A1 (en) | 1994-05-11 |
| WO1994010201A1 (en) | 1994-05-11 |
| AU5282193A (en) | 1994-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2432364C2 (ru) | ПОЛИКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ Nogo, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ АНТИТЕЛА ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА | |
| DE69931377T2 (de) | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren | |
| DE69027121T2 (de) | Bindeligande für tumornekrosisfaktor | |
| Hom et al. | The progression of the inflammation in established collagen‐induced arthritis can be altered by treatments with immunological or pharmacological agents which inhibit T cell activities | |
| US6682737B1 (en) | Anti-cryptosporidium parvum preparations | |
| KR920703036A (ko) | 자가면역 및 악성 질환 치료제로서의 t 세포 수용체 펩타이드 | |
| KR910000183A (ko) | 재조합 포자충증 백신 | |
| JPH05504554A (ja) | 免疫強化を促進するための方法と組成物 | |
| US20060275298A1 (en) | Antagonist of Th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases | |
| Hansen et al. | A mouse aminopeptidase N is a marker for antigen‐presenting cells and appears to be co‐expressed with major histocompatibility complex class II molecules | |
| JPH11505516A (ja) | 抗体クラススイッチを刺激する組成物及び方法 | |
| US20080282363A1 (en) | Methods for producing human antibodies in scid mice | |
| Shadduck et al. | Preparation and neutralization characteristics of an anti‐CSF antibody | |
| US7268219B1 (en) | Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means | |
| CA2264810A1 (en) | Method of producing active immunity with vaccine conjugate | |
| CA2055615A1 (en) | Monoclonal antibodies for inducing tolerance | |
| US20110182922A1 (en) | Peptides of il1 beta and tnf alpha and method of treatment using same | |
| EP1140168B1 (de) | Verwendung von antikörpern zur vakzinierung gegen krebs | |
| Aiuti et al. | Surface markers on human lymphocytes: studies of normal subjects and of patients with primary immunodeficiencies | |
| EP0003173A1 (en) | Process for producing human antibodies and composition containing them | |
| JPH01501793A (ja) | 透明帯に対する免疫化による避妊のための方法 | |
| EP0282343A2 (en) | Method to stimulate the immune response to specific antigens | |
| KR950704359A (ko) | 선충류 튜불린으로부터 유도된 펩티드 및 백신 | |
| WO1994028023A1 (en) | Cell surface protein expressed on human cortical thymocyte and their use | |
| JPH05504058A (ja) | 敗血症性ショック治療用医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |